GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Na
NHS England secures access to new cystic fibrosis treatment ALYFTREK
Vertex’s once-daily triple therapy approved for eligible patients a
MHRA approves first oral treatment for hereditary angioedema attacks
Sebetralstat offers injection-free relief for patients aged 12 and ov
Consumer health giant Kenvue kicks off CEO transition as sales slip
Along with the CEO transition announcement, the company disclosed pre
As Perrigo's streamlining takes shape, self-care specialist offloads OTC dermatology unit for up to €327M
Perrigo has agreed to sell its branded "dermacosmetics" business to K
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Na
NHS England secures access to new cystic fibrosis treatment ALYFTREK
Vertex’s once-daily triple therapy approved for eligible patients a
MHRA approves first oral treatment for hereditary angioedema attacks
Sebetralstat offers injection-free relief for patients aged 12 and ov
Consumer health giant Kenvue kicks off CEO transition as sales slip
Along with the CEO transition announcement, the company disclosed pre
As Perrigo's streamlining takes shape, self-care specialist offloads OTC dermatology unit for up to €327M
Perrigo has agreed to sell its branded "dermacosmetics" business to K
© 1994 - 2025 B.M. Pharmaceuticals